Dolors Dolors

Dolors

Colomer Pujol

Secondment

Group
Teràpies experimentals en neoplàsies limfoides
Team And Group Leader (R4)
2018-06-01

Research Fields

Research areas (short description)

Dolors Colomer was graduated in Chemistry (specialty in Biochemistry) at the University of Barcelona in 1984, and received her doctorate in 1990. She completed a postdoctoral stay at the Sloan Kettering Institute, New York, USA. at the laboratory of Dr. PA Marcks and RA Rifkind (1991), where she trained in the field of molecular biology. When she came back to Hospital Clinic she started a line of research focused in the analysis of new drugs for the treatment of hematological malignancies. She is currently Senior Consultant and Chief of the Hematopathology Section. She is the responsible of Molecular Biology Area, performing the assistance task of diagnosis and molecular monitoring of hematological neoplasms. It is a benchmark in Europe for the monitoring of minimal residual disease by quantitative PCR in chronic myeloid leukemia, centralizing most of the molecular studies of European clinical trials. She directs the research team of Experimental Therapeutic Targets in lymphoid malignancies at the IDIBAPS and she is the coordinator of the Hematology and Oncology area of IDIBAPS. Her research line focuses on the in vitro evaluation of the response of drugs and on the characterization of the mechanism of action of experimental or newly approved drugs for the treatment of lymphoid malignancies, basically focused on chronic lymphocytic leukemia (CLL) and on the mantle cell lymphoma (MCL). Their results have shown that in vitro experimental approaches using primary tumor cells and established human cell lines are useful in validating, with high reliability, the effect of selected drugs and have shown the importance of in vitro studies in the development of a drug for its application in the future to the clinic. The line of research has been financed continuously in the last 20 years. The group maintains a close collaboration with pharmaceutical companies and most of the studies have been done through Material Transfer Agreements (MTA) with companies for the joint development of new drugs. In addition, she actively collaborates in the majority of projects related to leukemia and lymphomas of our Institution, as well as with a large number of National and International groups. She is the Spanish representative of the molecular biology group of the European Leukemia network for CML (EUTOS). It is worth highlighting the active collaboration in the Genome Project of Chronic Lymphocytic Leukemia (International Genome Consortium of Cancer) and the European Mantle lymphoma Consortium. Also she has collaborated with the Grup d'Enginyeria Molecular of the Institut Quimic de Sarria in Barcelona in the design of a new group of molecules with tyrosine kinase activity. These molecules has been patented (No. EP13382225.4) and licensed to Pangea for its exploitation. Her group is recognized by the AGAUR (Catalan agency of Research) and she leads a researcher group at the CIBERONC (Centro de Investigación Biomedical En Red en Cancer), being the coordinator of the hematological tumors program within the CIBERONC. She has directed 8 doctoral theses and has published more than 200 scientific articles in high impact journals, being of publications as a senior author in D1 and Q1.Since 2018 she is Associate professor of Department of Basic Clinical Practice at the Faculty of Medicine at the University of Barcelona

Academic training

Publications

Agencies
Number of Documents
N Citations
h-index
Q1
D1
IFNA
IFNB
IFNESI
WoS
April 2025
530
24226
76
420
293
2.60
2.70
1.92
Scopus
April 2025
317
19731
70
248
175
2.39
2.85
-
Europe PMC
April 2025
303
15499
58
-
-
-
-
-
Dialnet
April 2025
1
-
-
-
-
-
-
-

Evolution

Internationalization

Altmetrics

Publications in social networks: 8 / 35
Percentage: 22.86%
Score: 88.428
Average score:
88.428 / 35 = 2.514

I+D+I Projects

Miembro
Coordinador/a
Doctoral Thesis
9

Subject / Course

Collaboration Network

Production